Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors

摘要

The present invention provides a compound of formula (I):;
said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

主权项

1. A compound or salt thereof selected from the group consisting of:
(R)—N-Hydroxy-2-[(1-hydroxy-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-3-methyl-butyramide; 2-[Benzyl-(7-ethoxy-naphthalene-2-sulfonyl)-amino]-N-hydroxy-3-methyl-butyramide; N-isoamyl-N-(6-ethyl naphthalene-2-sulfonyl)-D-valine hydroxamic acid; N-Hydroxy-2-[(6-hydroxy-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-3-methyl-butyramide; 2-[(6-Amino-naphthalene-2-sulfonyl)-(3-phenyl-propyl)-amino]-N-hydroxy-3-methyl-butyramide; 2-[(6-Acetylamino-naphthalene-2-sulfonyl)-(3-phenyl-propyl)-amino]-N-hydroxy-3-methyl-butyramide; N-isoamyl-N-(6-methoxy naphthalene-2-sulfonyl)-D-valine hydroxamic acid; N-isoamyl-N-(6-hydroxy naphthalene-2-sulfonyl)-D-valine hydroxamic acid; 2-[(7-Amino-naphthalene-2-sulfonyl)-(3-phenyl-propyl)-amino]-N-hydroxy-3-methyl-butyramide; (R)—N-Hydroxy-2-[(7-methoxy-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-3-methyl-butyramide; 2-[(6-Ethoxy-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-N-hydroxy-3-methyl-butyramide; 2-[Benzyl-(6-p-tolylamino-naphthalene-2-sulfonyl)-amino]-N-hydroxy-3-methyl-butyramide; N-Hydroxy-3-methyl-2-[[6-(3-methyl-butoxy)-naphthalene-2-sulfonyl]-(3-methyl-butyl)-amino]-butyramide; 2-[(7-Ethoxy-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-N-hydroxy-3-methyl-butyramide; N-Hydroxy-2-[(6-isobutoxy-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-3-methyl-butyramide; 2-[(6-Amino-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-N-hydroxy-3-methyl-butyramide; 2-[(6-Benzyloxy-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-N-hydroxy-3-methyl-butyramide; 2-[(6-Acetylamino-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-N-hydroxy-3-methyl-butyramide; N-Hydroxy-3-methyl-2-{(3-methyl-butyl)-[7-(3-methyl-butylamino)-naphthalene-2-sulfonyl]-amino}-butyramide; 2-[(7-Acetylamino-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-N-hydroxy-3-methyl-butyramide; 2-[(6-Allyloxy-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-N-hydroxy-3-methyl-butyramide; 2-[(7-Ethoxy-naphthalene-2-sulfonyl)-pyridin-3-ylmethyl-amino]-N-hydroxy-3-methyl-butyramide; (R)—N-Hydroxy-2-[(1-methoxy-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-3-methyl-butyramide; 2-[(1-Chloro-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-N-hydroxy-3-methyl-butyramide; 2-[(7-Amino-naphthalene-2-sulfonyl)-(3-methyl-butyl)-amino]-N-hydroxy-3-methyl-butyramide; N-isoamyl-N-(6-methyl naphthalene-2-sulfonyl)-D-valine hydroxamic acid; (R)—N-Hydroxy-3-methyl-2-[[7-(3-methyl-butoxy)-naphthalene-2-sulfonyl]-(3-methyl-butyl)-amino]-butyramide; and N-Hydroxy-3-methyl-2-[(3-methyl-butyl)-(6-propoxy-naphthalene-2-sulfonyl)-amino]-butyramide.